Cancer drug venetoclax takes aim at HIV's secret hiding spots
NCT ID NCT07481175
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether venetoclax, a drug used for certain blood cancers, can help eliminate the hidden HIV reservoir. The study enrolls 38 adults newly starting HIV therapy. Participants receive venetoclax in three short cycles while researchers monitor safety and measure changes in the amount of dormant HIV in their cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a drug that promotes cell death by blocking BCL-2)
What this could lead to
If it works, this could point toward a strategy to shrink the hidden HIV reservoir, potentially allowing people with HIV to stop lifelong medication in the future.
What could go wrong
This is a very early Phase 1 trial with only 38 participants. The drug may not reduce the reservoir enough, or could cause side effects. Even if successful, it is not a cure and further studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitari Germans Trias I Pujol, Department of Infectious Diseases
RECRUITINGBadalona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Infectious Diseases, Q Research
RECRUITINGAarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••